{"nctId":"NCT01319994","briefTitle":"Prevention of Metabolic Complications of Glucocorticoid Excess","startDateStruct":{"date":"2012-07"},"conditions":["Iatrogenic Cushing Disease"],"count":57,"armGroups":[{"label":"Metformin","type":"EXPERIMENTAL","interventionNames":["Drug: Metformin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Metformin","otherNames":["metformin tablet containing 850mg metformin"]},{"name":"Placebo","otherNames":["Placebo tablet matching the active drug tablet"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* patients diagnosed with an inflammatory condition and not started yet on GC treatment or • patients with an inflammatory condition treated with GC \\>20mg/d of prednisolone (or its cumulative equivalent) for at least 4wks\n* minimal duration of prospective therapy 12w\n* dose of prednisolone ≥10mg/d (or equivalent GC)\n* ambulatory patients\n* patients \\>18 years old\n* ability to understand verbal and written instructions and informed consent\n\nExclusion Criteria:\n\n* prior therapy with metformin during the last 6 months\n* known pre-existing diabetes\n* pregnancy\n* breastfeeding\n* liver impairment: ALT and/or AST ≥2.5 x UNL\n* renal impairment: serum creatinine levels ≥135.0 µmol/L in males and ≥110.0 µmol/L in females\n* current malignancy\n* patients unable to give written informed consent\n* or patients not understanding English","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"CT Abdomen","description":"change in visceral/subcutaneous fat","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.19"},{"groupId":"OG001","value":"-0.03","spread":"0.22"}]}]}]},{"type":"SECONDARY","title":"HOMA2-IR","description":"The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance and beta (β)-cell function. HOMA2-IR is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin resistance which is the reciprocal of insulin sensitivity (%S)(100/%S) as a percentage of a normal reference population (normal young adults). HOMA2-IR is calculated using the HOMA model: www.dtu.ox.ac.uk/homacalculator/","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":"3.26"},{"groupId":"OG001","value":"2.35","spread":"3.23"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":26},"commonTop":["Other","Gastrointestinal side-effects"]}}}